Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer

• Published in: In vivo (Athens) 2023-01, Vol.37 (1), p.143-148
• Main Authors: Ichihashi, Atsushi, Inamoto, Teruo, Uchimoto, Taizo, Nakamura, K O, Komura, Kazumasa, Yano, Yusuke, Nishimura, Kazuki, Kinoshita, Shoko, Nishio, Kyosuke, Fukushima, Tatsuo, Nakamori, Keita, Matsunaga, Tomohisa, Tsutsumi, Takeshi, Tsujino, Takuya, Uehara, Hirofumi, Takahara, Kiyoshi, Yamamoto, Kazuhiro, Kato, Ryuji, Ijiri, Yoshio, Hayashi, Tetsuya, Azuma, Haruhito
• Format: Article
• Language: English
• Subjects: Animals; Cisplatin - therapeutic use; Infusions, Intra-Arterial; Platinum; Rats; Tissue Distribution; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - pathology
• ISSN: 0258-851X; 1791-7549
• DOI: 10.21873/invivo.13063

In clinical practice, platinum-based systemic chemotherapy works to shrink pelvic lymph nodes. Intra-arterial (IA) bolus infusion may result in more favorable results than systemic chemotherapy. In the present study, we investigated the distribution of cisplatin administrated by IA infusion in varying organs, specifically focusing on the node tissue, in comparison with the intravenous (IV) route. Under anesthesia, cisplatin 0.42 mg/body was administrated by IA or IV infusion in rats to mimic a balloon-occluded arterial infusion model used in clinical practice. The kidney, bladder, lymphatic tissue, and peripheral blood were extracted to analyze the amount of cisplatin by inductively coupled plasma-mass spectrometry. Concertation of cisplatin by IA infusion was higher than that by the IV route in the peripheral blood and kidney. IA infusion led to a significantly high concentration of cisplatin in the bladder compared to IV infusion (1.3±0.452 vs. 0.2 ppb/mg ± 0.055, p=0.050). Furthermore, the IA method led to an extremely high concentration of cisplatin in the lymphatic tissue compared to the IV method (0.1±0.036 vs. 13.3±5.36, p=0.048). High cisplatin accumulation in the lymphatic tissue and bladder by IA administration may have a potential role for treating patients with node-positive bladder cancer.